Senate Judiciary Cmte. reports out S 343 in pre-recess version April 27 following brief, stormy session.
Executive Summary
SENATE JUDICIARY COMMITTEE REPORTS OUT REGULATORY REFORM BILL (S 343) April 27 under a unanimous consent agreement designed for the originally-scheduled April 26 mark-up. The mark-up was postponed one day due to the funeral of former Mississippi Sen. John Stennis (D). The unanimous consent was part of a compromise between Republicans and Democrats April 6 to convene a bipartisan task force, including Administration representatives, on the condition that the measure would be favorably reported out of the committee by April 26 at 6 p.m.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth